Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics (Nasdaq: CGEM) will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026 at 10:00 a.m. ET.
Rhea-AI Summary
Cullinan Therapeutics (Nasdaq: CGEM) will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026 at 10:00 a.m. ET. Speakers include CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A.
A live webcast will be available under the Events and Presentations section of the company’s investor relations website: https://investors.cullinantherapeutics.com/events.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CGEM
On Feb 18, the day this news came out, CGEM closed 2.05% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Summit date
- February 19, 2026
- Date of Citi 2026 Virtual Oncology Leadership Summit fireside chat
- Event time
- 10:00 a.m. ET
- Scheduled time of the Citi summit fireside chat
- Price change
- 5.18%
- CGEM 24-hour price change prior to this news
- 52-week range
- $5.68 – $13.43
- CGEM 52-week low and high before this news
- Market cap
- $684,693,842
- CGEM market capitalization prior to this announcement
- 200-day MA
- $8.69
- CGEM 200-day moving average before this news
- Relative volume
- 0.73x
- Today’s volume vs 20-day average ahead of this news
- Short interest
- 13.77%
- Reported short interest as share of float
Historical Context
-
Management fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
-
2026 pipeline milestones and cash runway update highlighting $439.0M liquidity.
-
Updated Phase 1 CLN-049 AML data with meaningful response rates and durability.
-
FDA Fast Track designation for CLN-049 in relapsed/refractory AML.
-
Initiation of rolling NDA submission for zipalertinib in EGFR ex20ins NSCLC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET.
A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Contacts:
Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.